Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials

202457 citationsJournal Articlehybrid Open Access

Authors

Deucravacitinib maintained efficacy and demonstrated consistent safety with no new safety signals observed through 2 years.

Good health and well-being

Published in: British Journal of Dermatology

Volume 190, Issue 5, pp. 668-679

Field-Weighted Citation Impact: 13.55